Vaporized, Inc. v. FDA
CourtCourt of Appeals for the Fifth Circuit
Date FiledNovember 18, 2026
Docket21-60779
StatusUnpublished
📰 News Coverage: Read the LAWS.com news report on this case
Full Opinion
Case: 21-60762 Document: 353-1 Page: 1 Date Filed: 11/18/2026
United States Court of Appeals
for the Fifth Circuit
____________ United States Court of Appeals
Fifth Circuit
FILED
No. 21-60762 November 18, 2026
____________
Thomas B. Plunkett, III
Clerk
SWT Global Supply, Incorporated,
Petitioner,
versus
Food & Drug Administration,
Respondent,
consolidated with
_____________
No. 21-60777
_____________
Cloud House, L.L.C.,
Petitioner,
versus
Food & Drug Administration,
Respondent,
consolidated with
_____________
No. 21-60778
Case: 21-60762 Document: 353-1 Page: 2 Date Filed: 11/18/2026
_____________
Paradigm Distribution,
Petitioner,
versus
Food & Drug Administration,
Respondent,
consolidated with
_____________
No. 21-60779
_____________
Vaporized, Incorporated,
Petitioner,
versus
Food & Drug Administration,
Respondent,
consolidated with
_____________
No. 21-60801
_____________
SV Packaging, L.L.C.,
Petitioner,
versus
2
Case: 21-60762 Document: 353-1 Page: 3 Date Filed: 11/18/2026
Food & Drug Administration,
Respondent.
______________________________
Petitions from the Food & Drug Administration
Agency Nos. PM0003792, PM0003640,
PM0000968, PM0001094, PM0001168,
PM0001191, PM0003578
______________________________
Before Elrod, Chief Judge, and Wiener and Wilson, Circuit Judges.
Per Curiam:*
These consolidated petitions are among many recent regulatory
disputes between the Food & Drug Administration (FDA) and e-cigarette
manufacturers. FDA issued marketing denial orders (MDOs) to SWT
Global Supply, Inc., Cloud House, L.L.C., Paradigm Distribution,
Vaporized, Inc., and SV Packaging, L.L.C. (collectively, Petitioners).
Petitioners then challenged the MDOs in this court. Based on our recent
decisions in similar cases, we grant the petitions for review, vacate the
MDOs, and remand to FDA for further proceedings.
I.
Petitioners initially sought review of the MDOs pertaining to their
e-cigarette products several years ago. We consolidated the petitions and
later granted them, following our decision in Wages & White Lion Invs.,
L.L.C. v. FDA, 90 F.4th 357 (5th Cir. 2024) (en banc). See SWT Glob.
Supply, Inc. v. FDA, 2024 WL 3595387, at *2 (5th Cir. July 31, 2024). FDA
then petitioned the Supreme Court for writs of certiorari in both Wages and
these cases. The Court granted the petitions, vacated the underlying
_____________________
*
This opinion is not designated for publication. See 5th Cir. R. 47.5.
3
Case: 21-60762 Document: 353-1 Page: 4 Date Filed: 11/18/2026
21-60762
c/w Nos. 21-60777, 21-60778, 21-60779, 21-60801
judgments, and remanded the cases to our court for further proceedings.
FDA v. Wages & White Lion Invs., L.L.C., 604 U.S. 542, 592 (2025); FDA v.
SWT Glob. Supply, Inc., 145 S. Ct. 1919, 1919 (2025) (Mem.) (remanding for
further consideration in light of Wages).
After the cases were remanded, FDA agreed to consider the
Petitioners’ proposed marketing plans. We granted the parties’ joint motion
to hold the petitions in abeyance pending the agency’s review. Following its
voluntary review, FDA maintained that the MDOs were appropriate. We
then removed the petitions from abeyance, and the parties filed supplemental
briefing addressing, inter alia, our recent cases addressing claims similar to
those raised by Petitioners here.
II.
The Family Smoking Prevention and Tobacco Control Act (TCA)
requires tobacco product manufacturers, including e-cigarette
1
manufacturers, to obtain FDA authorization before marketing their
products. 21 U.S.C. § 387j(a)(2)(A). One way they may do so is by
submitting premarket tobacco product applications to the agency. Id.
§ 387j(c)(1)(A)(i). In relevant part, the statute provides that FDA “shall
deny” an application that fails to show that marketing the product would be
“appropriate for the protection of the public health.” Id. § 387j(c)(2)(A).
FDA has determined that non-tobacco-flavored e-cigarettes (e.g.,
fruit- and mint-flavored) are especially dangerous for minors because those
e-cigarettes are more enticing than tobacco-flavored ones. VDX Distro, Inc.
v. FDA, 179 F.4th 356, 360 (5th Cir. 2026). Therefore, FDA will not deem
a non-tobacco-flavored e-cigarette “appropriate for the protection of the
_____________________
1
E-cigarette products count as “tobacco products” for purposes of the TCA. See
Wages & White Lion Invs., LLC, 604 U.S. at 551.
4
Case: 21-60762 Document: 353-1 Page: 5 Date Filed: 11/18/2026
21-60762
c/w Nos. 21-60777, 21-60778, 21-60779, 21-60801
public health” unless it carries an advantage over tobacco-flavored
e-cigarettes in helping adult cigarette smokers quit smoking or switch to
e-cigarettes—a balancing test referred to as the “comparative-efficacy
standard.” Id. at 362.
Applying the comparative-efficacy standard, FDA denied
Petitioners’ marketing applications for their non-tobacco-flavored
e-cigarettes. Petitioners challenged those MDOs on various grounds in their
initial petitions for review. But after years of intervening e-cigarette
litigation, Petitioners press one argument: that FDA’s comparative-efficacy
standard is a substantive rule adopted in violation of the Administrative
Procedure Act’s (APA) notice-and-comment requirements for rulemaking.
Our court recently addressed—and agreed with—this exact argument
in NicQuid, LLC v. FDA, 188 F.4th 790 (5th Cir. 2026). As we explained,
the FDA’s comparative-efficacy standard “constitutes a substantive rule.”
Id. at 803. The APA thus required the agency to undertake
notice-and-comment rulemaking before adopting the comparative-efficacy
standard. Id. at 806. Because FDA failed to do so, we vacated the agency’s
order denying the marketing application at issue. Id. at 809.
As FDA concedes, NicQuid “control[s] the outcome here.” For the
same reasons as articulated in NicQuid, these petitions for review are
GRANTED, the MDOs are VACATED, and these matters are
REMANDED to FDA for appropriate proceedings.
5